We hypothesized that radiation-induced thoracic toxicity (RITT) of the lung, esophagus and pericardium share a similar mechanism, and aimed to examine whether genetic variation of transforming growth factor-beta1 (TGFβ1), tissue plasminogen activator (tPA) and angiotensin converting enzyme (ACE), are associated with RITT in patients with non-small-cell lung cancer (NSCLC). Methods: Patients with stage I-III NSCLC were enrolled and received radiotherapy (RT). Blood samples were obtained pre-RT and at 4 to 5 weeks during RT, and plasma TGF-β1 was measured using an enzyme-linked immunosorbent assay. The DNA samples extracted from blood pre-RT were analyzed for the following frequent genetic variations: TGFβ1 509C/T, tPA -7351 C/T, and ACE I/D. RITT score was defined as the sum of radiation-induced toxicity grades in esophagus, lung, and pericardium. Results: Seventy-six NSCLC patients receiving definitive RT were enrolled. Patients with TGFß1 509CC had higher mean grade of esophagitis (1.4 ± 0.2 versus 0.8 ± 0.2, p = 0.019) and RITT score (2.6 ± 0.3 versus 1.6 ± 0.3, p = 0.009) than T allele carriers. Although no significant relationship was observed between RITT and the tPA or ACE variants individually, patients with any high-risk alleles (tPA CC or ACE D or TGFß1 509CC) had significantly higher grade of developing combined RITT (p < 0.001). Patients with TGFß1 509CC had greater increase of plasma TGF ß1 levels at 4 to 5 weeks during RT than T allele carriers did (CC 1.2 ± 0.2 versus T 0.7 ± 0.1, p = 0.047).
R adiation is the mainstay local treatment for patients with inoperable stage I-III non-small-cell lung cancer (NSCLC), and an adequate dose is essential for treatment success as increased radiation dose has been associated with reduction in risk of death. 1 However, the majority of patients with stage III NSCLC cannot receive an adequate dose for tumor control without exceeding the safe dose limits of the adjacent critical structures such as lung, esophagus, and heart. There are no reliable biologic markers to predict the risk of radiation-induced toxicity. Radiation doses during our standard practice are uniformly limited by the sensitive patient's tolerance. Despite this conservative approach, some patients develop severe toxicity, whereas the majority do not, suggesting that genetic makeup may play a critical role in an individual's response to radiotherapy (RT) and toxicity development. 2 Previous studies on radiation toxicity have been largely limited to specific organ toxicity; however, the biological mechanism of radiation toxicity in various organs at risk is likely to be similar. For example, inflammation is seen in esophagitis, pneumonitis and pericarditis. Genetic variations that lead to functional differences in proteins that participate in inflammatory processes may contribute to individual susceptibility to radiation-induced thoracic toxicity (RITT) including esophagitis, pneumonitis, pericarditis and pericardial effusion in patients with NSCLC.
Transforming growth factor-beta1 (TGF-β1) plays a crucial role in radiation-induced inflammation. 3 Tissue plasminogen activator (tPA) has been shown to participate in TGFβ1 activation, the regulation of inflammation, and the modulation of radiation-induced toxicity. 4, 5 In addition, angiotensin-converting enzyme (ACE) and its inhibitors may mitigate radiation-induced lung injury, 6, 7 possibly through the TGF-β1 pathway.
We hypothesized that the genetic variation of TGFβ1, tPA, and ACE are associated with accumulated overall RITT involving inflammation of lung, esophagus, and pericardium. We specifically selected the single nucleotide polymorphisms (SNPs), TGFβ1 509C/T, and tPA-7351 C/T, and the insertion (I)/deletion (D) polymorphism of ACE based on four criteria: (1) A minor allele frequency of at least 20% (~36% for rs1800469 TGFβ1 509C/T, 28% for rs2020918 tPA-7351 C/T, and 46% for rs4646994 I/D polymorphism of ACE;
(2) Functional location such as in the promoter untranslated region or coding region of the gene; (3) Reported association between the variant and its protein level; (4) Reported association with radiation injury induced inflammation or fibrosis.
MATERIALS AND METHODS

Study Population
The study population included the patients enrolled in Institutional Review Board approved prospective imaging and biomarker studies between 2003 and 2009 at our institutes. Written informed consent was obtained from each patient. Eligible subjects included patients with stages I-III NSCLC undergoing radiation alone or combined radiation and chemotherapy. Exclusion criteria included a life expectancy of less than 6 months, biopsy-proven supraclavicular lymphadenopathy, malignant pleural or pericardial effusion, or noncontiguous involvement of the parietal pleura. All radiation was given using three-dimensional conformal techniques, as previously described. 8, 9 Radiation dose was prescribed in majority of cases to a rate of 15 to 17% of lung normal tissue complication in our treatment studies, limited by 15% of normal tissue complication probability in imaging studies per standard care. Patients were seen weekly during RT, and then 1, 3, 6, 12, and 24 months after RT and assessed for RITT. The minimum follow-up duration was 12 months for surviving patients. The RITT score was defined as the sum of radiation-induced esophagus, lung, and pericardium toxicity grades. Radiation-induced lung toxicity (RILT) included pneumonitis and fibrosis, radiation-induced esophageal toxicity included dysphagia and odynophagia, and radiation-induced pericardium toxicity included pericardial effusion and pericarditis. All toxicities were graded prospectively per Common Terminology Criteria for Adverse Events version 3.0 (CTCAE3.0 http://ctep.cancer.gov/proto-colDevelopment/electronic_applications/docs/ctcaev3.pdf)
Sample Preparation and Plasma TGF-β1 Measurement
Blood samples were collected with Vacutainer Plus collection tubes (Becton, Dickinson and Co., Franklin Lakes, NJ) containing anticoagulant (dikalium salt of ethylenediaminetetraacetic acid [K2EDTA]) then placed in ice immediately after collection, and centrifuged within 3 hours of collection at 3000 g for 30 minute at 4°C. Plasma TGFβ1 levels were measured at baseline (within 2 weeks before RT start), and 4 to 5 weeks during RT. Plasma TGFβ1 levels were measured using a TGFβ1 specific Enzyme-Linked Immunosorbant Assay (Human TGFβ1 DuoSet kit, R&D Systems Inc., Minneapolis, MN).
Genotypes
The buffy coat was collected and stored at −80°C. The genomic analyses were performed on the DNA isolated from the buffy coat drawn from NSCLC patients within 2 weeks before RT start.
Genomic DNA was extracted from the buffy coat samples with a DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Polymerase chain reaction (PCR) and sequencing primers for the SNPs of TGFβ1 509C/T, and tPA-7351 C/T were designed using Pyrosequencing Primer Design Version1.0 software. PCR reactions were carried out in a 30-µl volume with 1.5 mmol/l Mg 2+ , 10 pmol of forward primer, and 10 pmol of reverse primer according to the following specifications: initial denaturation time of 5 minutes at 95°C followed by 45 cycles of 95°C for 30 seconds, 43°C for 30 seconds, 72°C for 30 seconds, and a final extension of 10 minutes at 72°C. Genotyping of TGFβ1 509C/T, and tPA-7351 C/T was carried out with Pyrosequencing Technology. 10 The I/D polymorphisms of ACE were examined by electrophoresis on 1.8% agarose gels stained with ethidium bromide after PCR. Specific assay conditions are available upon request.
Statistical Analysis
The relationship between the various SNPs and toxicity was assessed in numerous ways. In the primary analyses, genotype was treated as a binary covariate (CC versus T allele carrier for TGFβ1 and tPA, and I versus D allele carriers for ACE). The Cochrane-Armitage trend test was used to assess whether patients with one genotype tended to have higher (or lower) toxicity grades than patients with other genotypes did. Separate analyses were performed in which genotype was treated as categorical and ordinal. Other analyses were based on RITT and on definition of sensitive patients as those with any of three sensitive genotypes. However, given the exploratory nature of this work, no adjustments for multiplicity were made. All tests were two-sided and a p value less than 0.05 was considered statistically significant. Data are presented as mean+standard error of mean. The software package SAS (V9.2, Cary, North Carolina) was used for analysis.
RESULTS
Patient and Genotypes
From 2003 to 2009, 76 patients with stages I-III NSCLC requiring radiation-based therapy were enrolled in the study. All NSCLC patients received RT (a median dose of 66 Gy) and 56 of them (74%) underwent platinum-based concurrent chemotherapy. Among the patients with chemotherapy, 73% (41 of 56) received pacitaxol + carboplatin, 14% (8 of 56) received cisplatin and etoposide, and the remaining patients received other chemotherapy regimens. No significant differences in mean toxicity scores were found in lung (0.7 ± 0.1 versus 0.5 ± 0.3 versus 0.6 ± 0.3, p = 0.884), esophagus (1.0 ± 0.2 versus 1.3 ± 0.6 versus 1.6 ± 0.3, p = 0.435), pericardium (0.4 ± 0.1 versus 0.1 ± 0.1 versus 0.9 ± 0.1, p = 0.059) and combined RITT (2.1 ± 0.3 versus 1.9 ± 0.7 versus 3.0 ± 0.8, p = 0.381) among patients with pacitaxol + carboplatin, cisplatin + etoposide, and other chemo regimens.
Patient-, disease-, and treatment-related characteristics according to the genetic variations are shown in Table 1 . There were no significant differences between the genomic groups in age, sex, performance status, history of cardiovascular disease, chronic obstructive pulmonary disease, tumor histology, disease stage, receipt of chemotherapy versus RT only, and radiation dose received (p > 0.05 for all); the only difference noted was in the distribution of tPA-7351 C/T genotype among the different tobacco use groups (p = 0.02).
Genotype and Thoracic Toxicity
The distribution of various grades of toxicity is shown in Figure 1 . Patients with the TGFß1 CC genotype had higher grade of esophagitis than T allele carrier patients (CC 1.4 ± 0.2 versus T allele carriers 0.8 ± 0.2, p = 0.019). There was no significant difference in mean toxicity grade of lung (CC 0.8 ± 0.2 versus T allele carriers 0.5 ± 0.1, p = 0.179), and pericardium (CC 0.4 ± 0.1 versus T allele carriers 0.3 ± 0.1, p = 0.42), although those with the CC genotype had higher grade toxicities than T allele carriers. TGFß1 CC patients had significantly greater mean scores for all RITT than T allele carriers (CC 2.6 ± 0.3 versus T allele carriers 1.6 ± 0.3, p = 0.009) (Fig. 2 ). No significant difference was observed in any individual RITT or mean grade of RITT either between tPA-7351 CC and T allele carriers, or between ACE I and D allele carriers. Considering TGFβ1 CC, tPA CC, and ACE D allele carriers as sensitive genotypes, nine patients without these sensitive genotypes had significantly lower mean toxicity scores of esophagus (0 ± 0 versus 1.3 ± 0.1, p = 0.002), and lung (0 ± 0 versus 0.8 ± 0.1, p = 0.021 and all RITT (0.3 ± 0.2 versus 2.4 ± 0.2, p < 0.001) than those with sensitive genotypes, although their pericardium toxicity was not significantly different (0.3 ± 0.2 versus 0.4 ± 0.1, p = 0.787). However, no significant differences in mean toxicity scores were found in lung, esophagus, pericardium and combined RITT among patients with one, two, or three sensitive genotypes (RITT score 2.4 ± 0.3 versus 2.3 ± 0.3 versus 2.6 ± 0.7, p = 0.912).
Genotype and Plasma TGF β1
In the entire group of patients, the mean pre-RT TGFß1 level was 10.7 ± 2.3 ng/ml, and the mean during RT TGFß1 level was 6.0 ± 0.7 ng/ml. No significant differences in TGFß1 levels were found at pre-RT and during RT in patients with different genotypes of TGFß1 and tPA. Only patients with the ACE DD genotype had marginally higher pre-RT TGFß1 levels than patients with the II and ID genotypes did (DD 23.6 ng/ ml versus II 9.0 ng/ml versus ID 7.5 ng/ml, p = 0.05); there was no difference during RT (p = 0.346) or in the during-RT/pre-RT ratio (p = 0.433). However, patients with TGFß1 509CC had greater increase in plasma TGF ß1 level at 4 to 5 weeks during RT than T allele carriers (TGFß1 ratio of during-RT/ pre-RT were CC 1.2 ± 0.2 versus T allele carriers 0.7 ± 0.1, p = 0.047). ( Table 2) 
DISCUSSION
The data from the current study indicate that genetic variation of TGFβ1 pathway genes may be associated combined RITT in lung, esophagus, and pericardium. TGFβ1 -509 T allele carriers had significantly less severe radiation esophagitis (p = 0.019) and mean grade of RITT (p = 0.009) than TGFß1 CC patients. Patients with sensitive genotypes in this pathway had significantly higher grade of toxicity in lung, esophagus, and RITT than those without sensitive genotypes (p < 0.01)
The finding of the current study on TGFß1 pathway genotypes in all RITT has not been reported previously. From a biological standpoint, this finding is consistent with previous reports of TGFß1 in radiation normal tissue damage 11, 12 and that TGF-β1 levels may influence the pathologic process of radiation-induced inflammation and fibrosis. 3 Zhao et al. 13, 14 and Anscher et al. 15 have previously reported that radiationinduced elevations of plasma TGF-β1 levels during RT is predictive of RILT. The combination of TGF-β1 and mean lung dose may help stratify the patients for their risk of RILT. A normal plasma level of TGFβ1 by the end of RT was more common in patients without RILT. Changes in plasma TGF-β1 levels during RT were found to be useful in identifying patients at low risk for complications after radiation up to 86.4 Gy. 9 Fu et al. 16 reported that an elevated plasma TGFβ1 level at the end of RT is an independent risk factor for RILT. Novakova-Jiresova et al. 17 also observed a trend of plasma TGFβ1 concentration to decrease below the pretreatment value during the RT treatment in patients who did not develop pulmonary complications after the RT treatment.
Overall, the literature suggests a potential role of TGFβ1 in radiation lung damage and the value of using plasma TGFβ1 to predict RILT. However, measurement of plasma TGFβ1 is challenging for its reproducibility, as the plasma is easily contaminated with platelets. Testing with TGFß1 genotypes may accelerate the clinical application of TGFß1 in future clinical trial and practice. Genomic analysis is attractive for its resistance to variations in methodology of sample handing, as DNA is very stable. More importantly, risk assessment at baseline would provide an opportunity to individualize the entire course of treatment whereas assessment midtreatment will only guide the remaining treatment.
TGFβ1 SNPs are associated with TGFβ1 plasma level. Shah et al. 18 reported that the common functional SNPs of C-509T have been linked to a nearly twofold difference in plasma levels of TGFβ1. In this study, we found that patients with TGFß1 509CC had higher elevation of plasma TGF ß1 level at 4 to 5 weeks during RT than with T allele carriers. This may help explain the correlation between TGF ß1 level elevation and higher risk of radiation-induced lung toxicity, which was reported in our previous publications. [13] [14] [15] Therefore, it has been suggested that the molecular mechanism for the risk of radiation-induced lung toxicities may be linked to the SNPs of C-509T in TGFβ1gene. Yuan et al. 2 also reported high risk of radiation pneumonitis in patients exhibiting CC in TGF-β1-509C/T. Wang et al. 19 reported that genotype of TGF-β1-509C/T polymorphism was associated with the incidence of radiation-induced esophagus toxicity. Liu et al. 20 reported the pleiotropic effects of TGFβ1 on pericardial interstitial cells, implicating its effect for fibrosis and calcification in idiopathic constrictive pericarditis. The current study may serve as an independent validation of TGF-β1 in overall radiation injury in normal tissue. Patients expressing CC in TGFβ1-509C/T had significantly higher incidence of RITT and esophagitis and nonsignificant but increased toxicity score of lung and pericardium. If further validated in studies with a larger number of patients in a multicenter setting, TGFβ1-509C/T may be used as a convenient biomarker to individualize radiation therapy in lung cancer.
Considering TGFβ1, tPA, and ACE as parts of a single pathway, it can be shown that any functional variant of these proteins would change the sensitivity RITT of one individual. This was partly supported by the result of the current study in which patients without sensitive genetic variants in this pathway had significantly lower mean toxicity scores of esophagus (p = 0.002), lung (p = 0.021), and combined RITT (p < 0.001) than that of patients with any sensitive variant. It seems that one functional SNP in the pathway was sufficient to predispose a patient at higher risk as there was no significant difference in toxicity grade between patients with 1, 2 ,or 3 sensitive variants.
However, we acknowledge that this study is limited by its sample size, which may explain why we did not detect a difference in any RITT either between tPA-7351 CC and T allele carriers, or between ACE II and D allele carriers. The insignificant result of RITT with genotypes of tPA and ACE may indicate that TGFβ1 plays a more important role than either tPA or ACE in the complicated signal transduction pathway for radiationinduced normal tissue injury. Nevertheless, the association of the genotypes between TGF-β1 C-509T and grades of RITT support our hypothesis that radiation-inflammation-related toxicity of different organs may share a similar mechanism.
In summary, results from this hypothesis-driven study indicate that functional TGF-β1 genotypes C-509T may play an important role in the development of RITT, and future radiation toxicity studies may be carried out in patient level based on biologic mechanism. The approach of combining all RITT may have a greater impact on individualized care, as it provides an opportunity to assess the patient as a whole rather than organ by organ. Further study with a larger number of patients (ideally in a multicenter setting) is needed to validate our findings of the genetic variations in accumulative RITT.
